Fig 26 - by Piotr Popik (292215)

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Fig 26 - by Zhezhe Zhang (19704587)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Loss of RBM-26 causes mitochondria dysfunction in PLM. by Tamjid A. Chowdhury (14149846)

Mean confidence in public health organizations among US adults. by Hannah Melchinger (20234665)

The mean parasite concentration in the excreted urine of <i>Trypanosoma cruzi</i>-infected <i>Rhodnius prolixus</i> maintained at (A) 26°C and (B) 28°C at different triatomine deve... by Henri Loshouarn (17896676)

Loss of RBM-26 function causes a reduction in the density of mitochondria in the PLM axon. by Tamjid A. Chowdhury (14149846)

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, BCVA (logMAR ± standard deviation) showed no significant change from baselines (0.37 ± 0.20) to 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal–Wallis test, P = 0.45). …”

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

RBM-26 binds to the <i>mals-1</i> mRNA and negatively regulates its expression. by Tamjid A. Chowdhury (14149846)

Mean hemoglobin levels of Roxadustat and ESAs groups over time. by Jie Liu (15128)

Random forest plot showing the importance of predictors (top 10) for classifying LF progression based on the Mean Decrease in Gini index. by Emmanuel Kobla Atsu Amewu (13946765)

Loss of MALS-1 function suppresses the mitochondrial and axon degeneration phenotypes that are caused by loss of RBM-26 function. by Tamjid A. Chowdhury (14149846)

“…(D) Loss of RBM-26 protein expression causes a decrease in mitoribosome expression, which was assayed with the MitoRibo-Tag system consisting of the MRPL-58 mitoribosomal protein tagged at its C-terminus with 3XFLAG (MRPL-58::3XFLAG). …”

Overexpression of MALS-1 reduces mitochondria in the PLM axon and causes axon degeneration and axon overlap defects. by Tamjid A. Chowdhury (14149846)

“…(D–F) Overexpression of MALS-1 with the <i>Pmec-7</i>::<i>mals-1</i> transgenes (<i>cueEx53</i> and <i>cueEx54</i>) causes defects similar to those caused by loss of RBM-26 function. (D) Axon overlap defects caused by MALS-1 overexpression. …”

Summary of subgroup analysis results. by Junyin Pan (20700411)

“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”

Original study data. by Junyin Pan (20700411)

“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”

S2 File - by Junyin Pan (20700411)

“…The results showed that dietary anthocyanins significantly improved various lipid and glycemic markers:</p><p>HDL-C: increased by 0.05 mmol/L (95% CI: 0.01 to 0.10, p = 0.026), LDL-C: decreased by 0.18 mmol/L (95% CI: -0.28 to -0.08, p = 0.000), Triglycerides (TGs): reduced by 0.11 mmol/L (95% CI: -0.20 to -0.02, p = 0.021), Total cholesterol (TC): lowered by 0.34 mmol/L (95% CI: -0.49 to -0.18, p = 0.000), Fasting blood glucose (FBG): reduced by 0.29 mmol/L (95% CI: -0.46 to -0.12, p = 0.001), Glycated hemoglobin (HbA1c): decreased by 0.43% (95% CI: -0.74 to -0.13, p = 0.005). …”

Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup. by Jie Liu (15128)